<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240811</url>
  </required_header>
  <id_info>
    <org_study_id>PRO09100199</org_study_id>
    <nct_id>NCT01240811</nct_id>
  </id_info>
  <brief_title>Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception</brief_title>
  <acronym>CHIC</acronym>
  <official_title>Impact of Intrauterine Contraception on the Immune Environment of the Female Genital Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Achilles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is being performed to investigate the influence that starting contraception
      with an IUD has on the local immune cell populations and features, with a particular focus on
      the cells and cell-surface features that are important in HIV transmission (CD4 cells and
      CCR5 cell receptors).

      Based on results from large epidemiologic studies there seems to be a consistent finding of
      slightly increased HIV acquisition in women who use hormonal contraception. It is not clear
      if this is due to a biological phenomenon or if it relates to a difference in sexual
      behaviors/risks of women on hormonal contraceptives.

      The study hypothesis is that CD4 cells and CCR5 HIV-tropic receptor density increases within
      the upper and lower genital tract of women 2 months after placement of progestin-containing
      intrauterine devices for contraception as compared with women not using hormonal
      contraception.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium</measure>
    <time_frame>2 months</time_frame>
    <description>Change in CCR5 expression on T-lymphocytes 2 months after insertion of IUD (either hormonal LNG-IUD or non-hormonal Cu-IUD) in cervix and endometrium as measured by flow cytomety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vaginal Flora</measure>
    <time_frame>2 Months</time_frame>
    <description>Changes in vaginal flora as assessed by Nugent score The Nugent score is calculated by microscopically assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with bacterial vaginosis, 4-6 is consistent with intermediate vaginal flora, and 0-3 is normal vaginal flora.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis</measure>
    <time_frame>2 Months</time_frame>
    <description>Changes in vaginal flora as assessed by qPCR quantitation of H2O2 producing Lactobacilli species and Gardnerella vaginalis. Quantitative PCR (qPCR) results are reported as log concentration of gene copies/swab specimen.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Genital Tract Mucosal Immunity</condition>
  <condition>Genital Tract Microflora</condition>
  <arm_group>
    <arm_group_label>Control-No IUD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel IUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copper T380A IUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IUD placement</intervention_name>
    <description>Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).</description>
    <arm_group_label>Levonorgestrel IUS</arm_group_label>
    <arm_group_label>Copper T380A IUD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUD</intervention_name>
    <arm_group_label>Levonorgestrel IUS</arm_group_label>
    <other_name>Mirena IUD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper T380A IUD</intervention_name>
    <arm_group_label>Copper T380A IUD</arm_group_label>
    <other_name>ParaGard IUD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-pregnant, healthy females who are seeking an IUD for contraception

          2. Age 18-40 years, inclusive at the time of enrollment

          3. History of regular menstrual cycles defined as occurring every 21-35 days when not
             using hormones and with a variation of typical cycle length of no more than 5 days

          4. Willing and able to sign the informed consent and to comply with the study protocol

        Inclusion criteria for healthy control subjects:

          1. Non-pregnant, healthy females

          2. Age 18-40 years, inclusive at the time of enrollment

          3. History of regular menstrual cycles defined as occurring every 21-35 days when not
             using hormones and with a variation of typical cycle length of no more than 5 days

          4. Willing and able to sign the informed consent and to comply with the study protocol

          5. Prior surgical sterilization or heterosexually abstinent

        Exclusion Criteria:

          1. Use of any hormonal or intrauterine contraceptive method within the past two months

          2. Use of DMPA within the past 10 months

          3. Any of the following within the past two months:

               -  Pregnancy or breastfeeding

               -  Surgery/biopsy of the vulva, vagina, or cervix

               -  History of STI

               -  New sexual partner

          4. Evidence of vaginal/pelvic infection on screening

               -  Abnormal wet mount (see description above)

               -  Pelvic exam findings clinically consistent with infection

               -  Positive screen for Gc, Ct, or HIV (will be excluded post randomization)

          5. Active HSV/ulcerative disease in the genital tract or perineum

          6. History of immunosuppression (diabetes, HIV, chronic steroid use)

          7. Use of vaginal product (N9, microbicide, douche, antifungal, steroid, or hormone)
             within the past 30 days

          8. Use of any systemic or vaginal steroid or antibiotic within the past 30 days

          9. Vaginal or anal intercourse within 1 week of sample collection

         10. Heterosexual vaginal intercourse since last menses without condom use

         11. History of hysterectomy

         12. History of malignancy in the uterus or cervix

         13. Uterine anomaly (bicornuate uterus, uterine septum, or uterine didelphys)

         14. Allergy to copper and/or intolerance to levonorgestrel
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Achilles, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>January 15, 2013</results_first_submitted>
  <results_first_submitted_qc>June 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2013</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sharon Achilles</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>intrauterine device</keyword>
  <keyword>IUD</keyword>
  <keyword>levonorgestrel</keyword>
  <keyword>copper</keyword>
  <keyword>CD4</keyword>
  <keyword>CCR5</keyword>
  <keyword>microflora</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the medical clinic and our database of prior research participants. Public advertisements included listing on our website, letters to the database mailing list, flyers placed on local college campuses, mailings to faculty, internet postings on Craigâ€™s list, and informational booths at on or off campus fairs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control-No IUD</title>
          <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
        </group>
        <group group_id="P2">
          <title>Levonorgestrel IUS</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.</description>
        </group>
        <group group_id="P3">
          <title>Copper T380A IUD</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control-No IUD</title>
          <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
        </group>
        <group group_id="B2">
          <title>Levonorgestrel IUS</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.</description>
        </group>
        <group group_id="B3">
          <title>Copper T380A IUD</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6"/>
                    <measurement group_id="B2" value="26" spread="6"/>
                    <measurement group_id="B3" value="27" spread="4"/>
                    <measurement group_id="B4" value="26" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium</title>
        <description>Change in CCR5 expression on T-lymphocytes 2 months after insertion of IUD (either hormonal LNG-IUD or non-hormonal Cu-IUD) in cervix and endometrium as measured by flow cytomety</description>
        <time_frame>2 months</time_frame>
        <population>All 40 participants who completed the study were included in the analysis. There were no lost-to-follow up participants. One participant withdrew and one participant was excluded post-enrollment. Both of these participants were replaced to fill our goal enrollment of 40 participants in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Control-No IUD</title>
            <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
          </group>
          <group group_id="O2">
            <title>Levonorgestrel IUS</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.</description>
          </group>
          <group group_id="O3">
            <title>Copper T380A IUD</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.</description>
          </group>
        </group_list>
        <measure>
          <title>%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium</title>
          <description>Change in CCR5 expression on T-lymphocytes 2 months after insertion of IUD (either hormonal LNG-IUD or non-hormonal Cu-IUD) in cervix and endometrium as measured by flow cytomety</description>
          <population>All 40 participants who completed the study were included in the analysis. There were no lost-to-follow up participants. One participant withdrew and one participant was excluded post-enrollment. Both of these participants were replaced to fill our goal enrollment of 40 participants in the study.</population>
          <units>% of T-cells expressing CCR5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="17.2"/>
                    <measurement group_id="O2" value="11.7" spread="29.8"/>
                    <measurement group_id="O3" value="7.2" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vaginal Flora</title>
        <description>Changes in vaginal flora as assessed by Nugent score The Nugent score is calculated by microscopically assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with bacterial vaginosis, 4-6 is consistent with intermediate vaginal flora, and 0-3 is normal vaginal flora.</description>
        <time_frame>2 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control-No IUD</title>
            <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
          </group>
          <group group_id="O2">
            <title>Levonorgestrel IUS</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
IUD placement: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Levonorgestrel IUD</description>
          </group>
          <group group_id="O3">
            <title>Copper T380A IUD</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
IUD placement: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Copper T380A IUD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vaginal Flora</title>
          <description>Changes in vaginal flora as assessed by Nugent score The Nugent score is calculated by microscopically assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with bacterial vaginosis, 4-6 is consistent with intermediate vaginal flora, and 0-3 is normal vaginal flora.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-7" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="-3" upper_limit="6"/>
                    <measurement group_id="O3" value="0" lower_limit="-8" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in paired change in Nugent score from baseline to 2 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis</title>
        <description>Changes in vaginal flora as assessed by qPCR quantitation of H2O2 producing Lactobacilli species and Gardnerella vaginalis. Quantitative PCR (qPCR) results are reported as log concentration of gene copies/swab specimen.</description>
        <time_frame>2 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control-No IUD</title>
            <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
          </group>
          <group group_id="O2">
            <title>Levonorgestrel IUS</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
IUD placement: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Levonorgestrel IUD</description>
          </group>
          <group group_id="O3">
            <title>Copper T380A IUD</title>
            <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
IUD placement: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Copper T380A IUD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis</title>
          <description>Changes in vaginal flora as assessed by qPCR quantitation of H2O2 producing Lactobacilli species and Gardnerella vaginalis. Quantitative PCR (qPCR) results are reported as log concentration of gene copies/swab specimen.</description>
          <units>log gene copies/swab</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in log Lactobacilli quantity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-4.5" upper_limit="3.1"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-8.3" upper_limit="1.0"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-3.1" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in log Garnerella vaginalis quantity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0" lower_limit="-5.1" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0" lower_limit="-7.1" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in quantity of H2O2 producing Lactobacilli species by qPCR</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in quantity of Garnerella vaginalis species by qPCR</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control-No IUD</title>
          <description>Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.</description>
        </group>
        <group group_id="E2">
          <title>Levonorgestrel IUS</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.</description>
        </group>
        <group group_id="E3">
          <title>Copper T380A IUD</title>
          <description>Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We identified a need for methods optimization prior to proceeding with a large definitive study to determine contraceptive hormone induced changes in genital tract immune cell populations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sharon Achilles, MD, PhD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-641-1403</phone>
      <email>achisx@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

